Inflammatory Bowel Disease
Conditions
Brief summary
The study is being conducted to evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of HRS-7085.
Interventions
DRUGHRS-7085 tablets
Single oral administration
DRUGPlacebo tablet
Single oral administration
Sponsors
Atridia Pty Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Intervention model description
Part 1: HRS-7085 Single Ascending Dose (SAD) Both males and females are planned to be enrolled in five cohorts (optional and determined by Safety Review Committee (SRC) in this SAD study Part 2: Food Effect: Participants in cohort 3 who have finished the follow-up visit will be involved in the food effect study after safety evaluation by the investigator.
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
1. Ability to understand the trial procedures and possible adverse events, volunteers to participate in the trial. 2. Male or female aged between 18 years and 55 years (inclusive) at the date of signed consent form. 3. Total body weight 45 kg\ 100 kg (inclusive) at screening, and body mass index (BMI) between 18 and 32 kg/m2 (inclusive). 4. For healthy subjects, no clinically significant abnormalities. 5. Men and women of childbearing potential (WOCBP) must agree to take effective contraceptive methods
Exclusion criteria
1. Known medical history of severe disease in cardiovascular, liver, kidney, digestive tract, mental nerve, hematology, metabolic disorders, etc. 2. Severe injuries or major surgeries within 3 months before dosing. 3. Subjects with infectious disease. 4. Live/attenuated vaccine within 3 months prior to dosing or any vaccine during the trial. 5. Blood donation or loss of ≥ 200 mL of blood within 1 month prior to dosing, or ≥ 400 mL of blood within 3 months prior to dosing; or receive a blood transfusion within 2 months prior to dosing. 6. Clinically significant abnormalities in 12-Lead ECG 7. More than 5 cigarettes daily (or products with equivalent amount of nicotine) for 3 months prior to screening, or positive cotinine test at screening or baseline. 8. Positive urine drug at screening or baseline. 9. Subject who cannot perform venous blood sampling. 10. Known history or suspected of being allergic to the study drugs and their excipients. 11. Use of prescription medicine within 2 weeks, or OTC medicine, within 1-week or 5 half-lives prior to dosing. 12. History of alcohol abuse within 3 months prior to screening, or positive alcohol breath test at screening or baseline. 13. Participation in clinical trials of other investigational drugs or medical devices within 1 month or 5 half-lives prior to dosing. 14. Special dietary requirements that cannot follow the meal plan in the food effect study. 15. In the investigator's judgment, may increase the risk to the subject. 16. Unwilling or unable to comply with the Lifestyle Guidelines detailed in this protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence and severity of adverse events | Start of Treatment to end of study approximately 1 week |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics-AUC0-inf | Start of Treatment to end of study (approximately 1 week) | Area under the concentration-time curve from time 0 to infinity after HRS-7085 administration |
| Pharmacokinetics-Tmax | Start of Treatment to end of study (approximately 1 week) | Time to Cmax of HRS-7085 |
| Pharmacokinetics-Cmax | Time Frame: Start of Treatment to end of study (approximately 1 week) | Maximum observed concentration of HRS-7085 |
| Pharmacokinetics-AUC0-last | Start of Treatment to end of study (approximately 1 week) | Area under the concentration-time curve from time 0 to last time point after HRS-7085 administration |
| Pharmacokinetics-Vz/F | Time Frame: Start of Treatment to end of study (approximately 1 week) | Apparent volume of distribution during terminal phase of HRS-7085 |
| Pharmacokinetics-t1/2 | Time Frame: Start of Treatment to end of study (approximately 1 week) | Terminal elimination half-life of HRS-7085 |
| Pharmacokinetics-CL/F | Time Frame: Start of Treatment to end of study (approximately 1 week) | Apparent clearance of HRS-7085 |
Countries
Australia
Outcome results
None listed